Patricia Kropf on Home Administration of Synribo for CML

Article

Patricia Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses home administration of Synribo (omacetaxine mepesuccinate).

Patricia Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses home administration of Synribo (omacetaxine mepesuccinate).

In May 2014, the FDA approved home administration of the subcutaneous injection for patients with chronic myelogenous leukemia (CML) who are resistant or intolerant to treatment with tyrosine-kinase inhibitors (TKIs).

Prior to the approval, patients had to travel to the clinic to receive their injections, which Kropf says was burdensome and inconvenient. The injections can be administered by the patients or caregivers.

Kropf adds that she anticipates seeing an expansion of Synribo prescriptions because of the approval.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a man with a beard in front of a blue background
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Related Content